SCANDENT fair value: what the stock is really worth
As of Sep 22, 2026: fair value of SCANDENT ₹4.75, price ₹2.01, upside +136.3%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch SCANDENT for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹1.91 – ₹52.97 · fair‑value band ₹2.32 – ₹5.94 · the ₹2.01 price screens below the ₹4.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow SCANDENT in your weekly email
Every Wednesday you see whether SCANDENT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
SCANDENT (SCANDENT) currently trades at ₹2.01, while our model-based Fair Value estimate is ₹4.75, implying the stock looks roughly 57.7% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹9.60 per share, and 21 of the 24 models we run sit above the ₹2.01 price.
Bear case: the Growth DCF group reads lowest at ₹1.90, and 3 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹2.32 (bear) to ₹5.94 (bull), the price of ₹2.01 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Health Care sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
SCANDENT reported revenue of ₹421M in FY2021 versus ₹51.9M in FY2017, a compound +68.7%/yr. Reported net income was ₹52.0M in FY2021, compounding +56.9%/yr from FY2017.
Key figures
Market cap ₹506M (≈ $5.3M) · P/E ratio 23.0 · P/S ratio 2.85 · Net margin 12.4% · Return on assets (EBIT) 14.0% · Free cash flow ₹13.5M · Net debt ₹40.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 64% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −50% fair-value upside, at 136%, SCANDENT screens cheaper than that median.
Fair Value models
Bear ₹2.32Fair Value ₹4.75Bull ₹5.94
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+43.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+87.9%
’16
’17
’18
’19
’20
’21
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+68.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+68.1%
Dividend (yield on the price)0.0%
Profit margin 2016 to 2021 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 17%
2021 sits 18,166% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−38.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −41.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Hospitals” was too small, so the broader sector is used.)Health Care · 2614 stocks
Beats the sector median on 4/8 measures
A mixed picture versus its sector peers.
Valuation
Quality Score53 · Above median
Fair Value upside+136% · Top 25%
Profitability
Return on assets0% · Below median
Net margin (TTM)12% · Above median
Operating margin (TTM)0% · Below median
Growth and dividend
Revenue growth0% · Below median
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "SCANDENT Fair Value". https://www.fairvalue-calculator.com/stock/SCANDENT
Frequently asked questions
Is SCANDENT overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹4.75 versus a price of ₹2.01, about +136% upside (undervalued).
What is the fair value of SCANDENT?
Our model-based fair value for SCANDENT is ₹4.75 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹2.01.
What is the quality score of SCANDENT?
SCANDENT has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SCANDENT?
Our model-based price target is the fair value of ₹4.75 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario ₹2.32, optimistic scenario ₹5.94. It is a calculation from audited fundamentals, not an analyst target.
What is the SCANDENT stock forecast for 2026?
Our models put fair value at ₹4.75, about +136% upside versus a price of ₹2.01 (undervalued). Cautious scenario ₹2.32, optimistic scenario ₹5.94. The calculation is refreshed regularly with new filings.
What growth is priced into SCANDENT?
For today's price to be fair in a discounted-cash-flow model, SCANDENT would have to grow free cash flow by -38.9 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +87.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of SCANDENT use?
Our models discount SCANDENT at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For SCANDENT that is -38.9 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has SCANDENT delivered so far?
Over the past 5 years revenue at SCANDENT grew +87.9 % a year. The price currently implies -38.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of SCANDENT?
The free-cash-flow yield on the price is 20.92 %: that much free cash flow SCANDENT produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of SCANDENT?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SCANDENT it is ₹4.75 per share (as of Sep 24, 2026), against a price of ₹2.01. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is SCANDENT stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SCANDENT trades below its calculated fair value: price ₹2.01, fair value ₹4.75, a gap of about +136% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SCANDENT?
No. The price is what the market pays today (₹2.01); the fair value is what the company's own numbers justify (₹4.75). For SCANDENT the two are ₹2.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is SCANDENT worth?
The market values SCANDENT at about ₹506M (market capitalisation, as of Sep 24, 2026). Per share that is ₹2.01; our models calculate a fair value of ₹4.75 per share.
What do the bullish and bearish scenarios say about SCANDENT?
Our models span a range for SCANDENT: cautious scenario ₹2.32, base ₹4.75, optimistic ₹5.94 per share (as of Sep 24, 2026, price ₹2.01). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SCANDENT?
SCANDENT trades at a price-to-earnings ratio of 23.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹4.75 is built from several models across several years.
How solid is the balance sheet of SCANDENT?
Balance-sheet figures for SCANDENT (as of Sep 24, 2026): debt of 0.12 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is SCANDENT from its 52-week high?
SCANDENT trades at ₹2.01, about 64% below its 52-week high of ₹5.62 and 5% above the low of ₹1.91 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ₹4.75 is for.
Which stocks are comparable to SCANDENT?
From the same area (Health Care) we also value KMCSHIL, 516110, PINC, SHUKRAPHAR, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SCANDENT stock attractive at the current price?
The data as of Sep 24, 2026: price ₹2.01, calculated fair value ₹4.75 (+136%), Quality Score 53/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SCANDENT calculated?
We run SCANDENT through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹4.75, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. SCANDENT currently trades 136 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SCANDENT?
The closing price on Sep 22, 2026 was ₹2.01. Our model-based fair value is ₹4.75, about +136% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SCANDENT right now?
The price is below even our cautious bear case (₹2.32). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (₹2.32 to ₹5.94) leaves room in how you read the outcome.
Key figures of SCANDENT
How large is the market capitalisation of SCANDENT?
The market capitalisation of SCANDENT is ₹506M (≈ $5.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SCANDENT?
The price-to-sales ratio of SCANDENT is 2.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of SCANDENT?
The net margin of SCANDENT is 12.4% (fiscal year 2021). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of SCANDENT?
On an EBIT basis the return on assets of SCANDENT is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net debt does SCANDENT carry?
The net debt of SCANDENT is ₹40.5M (fiscal year 2021, ≈ 3.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch SCANDENT in the live analysis
One click puts SCANDENT on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
